As the MMP-2/TIMP-2 system contributes to the pathogenesis of atherosclerosis, cardiovascular disease, and the progression of CKD, our findings suggest an underlying pharmacological rationale for the use of β-blockers in clinical practice to reduce inflammation and abnormal vascular remodeling, which predispose the patients with CKD to increased cardiovascular events. This evidence concerns the gene TIMP2 and chronic kidney disease.